It was reported that Gal1 is involved in pathological NV and its therapeutic targeting attenuates aberrant angiogenesis in cancer and endometriosis [17, 18, 48–51]; however its role in neovascular retinopathies is still uncertain. Here, LGALS1 is linked to retinal disorder.